(Q46522487)

22 December 2017

title

Pilot study of minocycline in relapsing-remitting multiple sclerosis (English)

1 reference

22 December 2017

relapsing-remitting multiple sclerosis

main subject

multiple sclerosis

0 references

0 references

1 reference

Yunyan Zhang

1

1 reference

22 December 2017

Luanne M Metz

2

1 reference

22 December 2017

V Wee Yong

3

1 reference

22 December 2017

Robert B Bell

4

1 reference

22 December 2017

Michael Yeung

5

1 reference

22 December 2017

David G Patry

6

1 reference

22 December 2017

J Ross Mitchell

7

1 reference

22 December 2017

publication date

1 May 2008

1 reference

22 December 2017

Canadian Journal of Neurological Sciences

published in

1 reference

22 December 2017

volume

35

1 reference

22 December 2017

issue

2

1 reference

22 December 2017

page(s)

185-191

1 reference

22 December 2017

Inhibition of autoimmune encephalomyelitis by a tetracycline.

cites work

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100008611

7 January 2021

The promise of minocycline in neurology.

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100008611

7 January 2021

Targeting leukocyte MMPs and transmigration: minocycline as a potential therapy for multiple sclerosis

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100008611

7 January 2021

A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100008611

7 January 2021

Magnetic resonance imaging results of the PRISMS trial: a randomized, double-blind, placebo-controlled study of interferon-beta1a in relapsing-remitting multiple sclerosis. Prevention of Relapses and Disability by Interferon-beta1a Subcutaneously in

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100008611

7 January 2021

Minocycline reduces gadolinium-enhancing magnetic resonance imaging lesions in multiple sclerosis.

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100008611

7 January 2021

Contrast-enhanced MRI lesions during treatment with interferonbeta-1b predict increase in T1 black hole volume in patients with relapsing-remitting multiple sclerosis.

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100008611

7 January 2021

Rate of brain atrophy in relapsing MS decreases during treatment with IFNbeta-1a.

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100008611

7 January 2021

The neuroimmunology of multiple sclerosis: possible roles of T and B lymphocytes in immunopathogenesis

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100008611

7 January 2021

Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFNB Multiple Sclerosis Study Group

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100008611

7 January 2021

The variability of manual and computer assisted quantification of multiple sclerosis lesion volumes

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100008611

7 January 2021

Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. UBC MS/MRI Study Group and the IFNB Multiple Sclerosis Study Group

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100008611

7 January 2021

Additive effect of the combination of glatiramer acetate and minocycline in a model of MS.

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100008611

7 January 2021

Multiple neuroprotective mechanisms of minocycline in autoimmune CNS inflammation

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100008611

7 January 2021

Interferon beta-1b decreases the migration of T lymphocytes in vitro: effects on matrix metalloproteinase-9.

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100008611

7 January 2021

Effect of minocycline in experimental autoimmune encephalomyelitis

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100008611

7 January 2021

Short term predictors of unemployment in multiple sclerosis patients

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100008611

7 January 2021

Computer-assisted identification and quantification of multiple sclerosis lesions in MR imaging volumes in the brain

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100008611

7 January 2021

Accurate, robust, and automated longitudinal and cross-sectional brain change analysis

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100008611

7 January 2021

Measurement of atrophy in multiple sclerosis: pathological basis, methodological aspects and clinical relevance

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100008611

7 January 2021

Serum MMP-9/TIMP-1 and MMP-2/TIMP-2 ratios in multiple sclerosis: relationships with different magnetic resonance imaging measures of disease activity during IFN-beta-1a treatment

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100008611

7 January 2021

Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100008611

7 January 2021

Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100008611

7 January 2021

https://api.crossref.org/works/10.1017%2FS0317167100008611

1 reference

7 January 2021

Eight-year follow-up study of brain atrophy in patients with MS.

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100008611

7 January 2021

Effective combination of minocycline and interferon-beta in a model of multiple sclerosis

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100008611

7 January 2021

Gelatinase B/matrix metalloproteinase-9 cleaves interferon-beta and is a target for immunotherapy

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100008611

7 January 2021

European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging-measured disease activity and burden in patients with relapsing multiple sclerosis

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100008611

7 January 2021

Metalloproteinases in biology and pathology of the nervous system.

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100008611

7 January 2021

The clinical response to minocycline in multiple sclerosis is accompanied by beneficial immune changes: a pilot study

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100008611

7 January 2021

Defining the clinical course of multiple sclerosis: Results of an international survey

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100008611

7 January 2021

Immunotherapy of multiple sclerosis: where are we? Where should we go?

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100008611

7 January 2021

10.1017/S0317167100008611

Identifiers

DOI

0 references

1 reference

22 December 2017